Clinical trial · Observational
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
NCT06295965CI-TRIAL-00108639recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clonal Cytopenia of Undetermined Significance | — | UNRESOLVED | — |
| Clonal Hematopoiesis | — | UNRESOLVED | — |
| Idiopathic Cytopenia of Undetermined Significance | — | UNRESOLVED | — |
| Myeloid Neoplasm Post Cytotoxic Therapy | Myeloid Neoplasm Post Cytotoxic Therapy | ONTOLOGY_EXACT | 0.98 |
| Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder | — | UNRESOLVED | — |
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Recurrent Fallopian Tube Carcinoma | Fallopian Tube Carcinoma | CURATED_BROADER | 0.78 |
| Recurrent Malignant Solid Neoplasm | Malignant Solid Neoplasm | CURATED_BROADER | 0.78 |
| Recurrent Ovarian Carcinoma | Ovarian Carcinoma |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
- interventionNames
- Other: Non-Interventional Study
Primary outcomes (3)
- measure
- Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients
- timeFrame
- Through study completion, up to 5 years
- measure
- Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors
- timeFrame
- Through study completion, up to 5 years
- description
- Measurement Tool: will measure by BM biopsy confirmation done by local hematologist
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and: * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy OR * Subjects who have or have had a solid tumor diagnosis and any of the following: * At least 4 months of exposure to a PARP inhibitor * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm Exclusion Criteria: * Individuals with a life expectancy of less than 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.